Literature DB >> 17617576

KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro.

Joseph H Chewning1, Charlotte N Gudme, Katharine C Hsu, Annamalai Selvakumar, Bo Dupont.   

Abstract

The inhibitory 2DL1 and activating 2DS1 killer Ig-like receptors (KIR) both have shared ligand specificity for codon sequences in the C2 group HLA-Cw Ags. In this study, we have investigated NK cell activation by allogeneic target cells expressing different combinations of the HLA-KIR ligand groups C1, C2, and Bw4. We demonstrate that fresh NK cells as well as IL-2-propagated NK cells from 2DS1-positive donors that are homozygous for the C1 ligand group are activated in vitro by B lymphoblastoid cell lines expressing the C2 group. This response is, in part, due to the absence of C1 group recognition mediated by the inhibitory receptor 2DL2/3. This "missing self" alloresponse to C2, however, is rarely observed in NK cells from donors lacking 2DS1. Even in presence of 2DS1, the NK alloresponse is dramatically reduced in donors that have C2 group as "self." Analysis of selected NK clones that express 2DS1 mRNA and lack mRNA for 2DL1 demonstrates that activation by the C2 ligand and mAb cross-linking of 2DS1 in these clones induces IFN-gamma. Furthermore, this C2 group-induced activation is inhibited by Abs to both HLA class I and the receptor. Collectively, these studies demonstrate that NK cells from 2DS1-positive donors are activated by target cells that express the C2 group as an alloantigen. This leads to increased IFN-gamma-positive fresh NK cells and induces NK allocytotoxicity in IL2-propagated polyclonal NK cells and NK clones. This study also provides support for the concept that incompatibility for the HLA-KIR ligand groups C1, C2, and Bw4 dominates NK alloactivation in vitro.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617576     DOI: 10.4049/jimmunol.179.2.854

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2.

Authors:  Susan E Hiby; Richard Apps; Andrew M Sharkey; Lydia E Farrell; Lucy Gardner; Arend Mulder; Frans H Claas; James J Walker; Christopher W Redman; Christopher C Redman; Linda Morgan; Clare Tower; Lesley Regan; Gudrun E Moore; Mary Carrington; Ashley Moffett
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

2.  Activating Receptors for Self-MHC Class I Enhance Effector Functions and Memory Differentiation of NK Cells during Mouse Cytomegalovirus Infection.

Authors:  Tsukasa Nabekura; Lewis L Lanier
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

3.  Permanent silencing of NKG2A expression for cell-based therapeutics.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2008-11-11       Impact factor: 4.599

4.  DAP12 impacts trafficking and surface stability of killer immunoglobulin-like receptors on natural killer cells.

Authors:  Tiernan J Mulrooney; Phillip E Posch; Carolyn Katovich Hurley
Journal:  J Leukoc Biol       Date:  2013-05-28       Impact factor: 4.962

5.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.

Authors:  David Avigan; Parameswaran Hari; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Katharine C Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-07       Impact factor: 5.742

6.  Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies.

Authors:  Letizia Muccio; Alice Bertaina; Michela Falco; Daniela Pende; Raffaella Meazza; Miguel Lopez-Botet; Lorenzo Moretta; Franco Locatelli; Alessandro Moretta; Mariella Della Chiesa
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

Review 7.  Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection.

Authors:  Katharina Fleischhauer; Katharine C Hsu; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-05-24       Impact factor: 5.483

Review 8.  Strategies to enhance NK cell function for the treatment of tumors and infections.

Authors:  Jacquelyn Freund-Brown; Leilani Chirino; Taku Kambayashi
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

9.  Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Authors:  Wei Wang; Amy K Erbe; Mikayla Gallenberger; KyungMann Kim; Lakeesha Carmichael; Dustin Hess; Eneida A Mendonca; Yiqiang Song; Jacquelyn A Hank; Su-Chun Cheng; Sabina Signoretti; Michael Atkins; Alexander Carlson; Jonathan M Weiss; James Mier; David Panka; David F McDermott; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-09-30       Impact factor: 6.968

10.  Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation.

Authors:  Shiqiu Xiong; Andrew M Sharkey; Philippa R Kennedy; Lucy Gardner; Lydia E Farrell; Olympe Chazara; Julien Bauer; Susan E Hiby; Francesco Colucci; Ashley Moffett
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.